Patents by Inventor David Orain

David Orain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF
    Publication number: 20240043425
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 18, 2023
    Publication date: February 8, 2024
    Inventors: Mallesh BUSHABOINA, Xin CHEN, Atwood Kim CHEUNG, Andrew James CULSHAW, Timothy Brian HURLEY, Nancy LABBE-GIGUERE, Wolfgang MILTZ, David ORAIN, Tajesh PATEL, Srinivasan RAJAGOPALAN, Till ROEHN, David Andrew SANDHAM, Gebhard THOMA, Ritesh Bhanudasji TICHKULE, Rudolf WÄLCHLI
  • INTERLEUKIN-17 INHIBITORS
    Publication number: 20230391782
    Abstract: The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.
    Type: Application
    Filed: November 1, 2021
    Publication date: December 7, 2023
    Inventors: Thomas Josef TROXLER, David ORAIN, Pascal FURET, Klaus WEIGAND, Achim SCHLAPBACH
  • Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
    Patent number: 11708366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Novartis AG
    Inventors: Mallesh Bushaboina, Xin Chen, Atwood Kim Cheung, Andrew James Culshaw, Timothy Brian Hurley, Nancy Labbe-Giguere, Wolfgang Miltz, David Orain, Tajesh Patel, Srinivasan Rajagopalan, Till Roehn, David Andrew Sandham, Gebhard Thoma, Ritesh Bhanudasji Tichkule, Rudolf Wälchli
  • HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF
    Publication number: 20220048909
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Inventors: Mallesh BUSHABOINA, Xin CHEN, Atwood Kim CHEUNG, Andrew James CULSHAW, Timothy Brian HURLEY, Nancy LABBE-GIGUERE, Wolfgang MILTZ, David ORAIN, Tajesh PATEL, Srinivasan RAJAGOPALAN, Till ROEHN, David Andrew SANDHAM, Gebhard THOMA, Ritesh Bhanudasji TICHKULE, Rudolf WÄLCHLI
  • DIAZEPINONE DERIVATIVES
    Publication number: 20170305903
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Diazepinone derivatives
    Patent number: 9650377
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Dirk Behnke, David Carcache, Peter Ertl, Manuel Koller, David Orain
  • DIAZEPINONE DERIVATIVES
    Publication number: 20160159795
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Diazepinone derivatives
    Patent number: 9284331
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: March 15, 2016
    Assignee: Novartis AG
    Inventors: Dirk Behnke, David Carcache, Peter Ertl, Manuel Koller, David Orain
  • DIAZEPINONE DERIVATIVES
    Publication number: 20140357625
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Diazepinone derivatives
    Patent number: 8853203
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: October 7, 2014
    Assignee: Novartis AG
    Inventors: Dirk Behnke, David Carcache, Peter Ertl, Manuel Koller, David Orain
  • Diazepinone derivatives
    Publication number: 20140057902
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Use of 1H-Quinazoline-2,4-Diones
    Publication number: 20140018376
    Abstract: The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of Rasmussen's encephalitis and/or certain forms of epilepsy.
    Type: Application
    Filed: October 20, 2010
    Publication date: January 16, 2014
    Inventors: Hans Allgeier, Yves Auberson, Thomas Blaettler, David Carcache, Philipp Floersheim, Wolfgang Froestl, Christel Guibourdenche, Hans o Kalkman, Joerg Kallen, Manuel Koller, Kurt Lingenhohl, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud, Christine Strohmaier
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20130296332
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 1, 2013
    Publication date: November 7, 2013
    Inventors: Hans ALLGEIER, Yves AUBERSON, David CARCACHE, Philipp FLOERSHEIM, Christel GUIBOURDENCHE, Wolfgang FROESTL, Jörg KALLEN, Manuel KOLLER, Henri MATTES, Joachim NOZULAK, David ORAIN, Johanne RENAUD
  • 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
    Publication number: 20130274294
    Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 17, 2013
    Inventors: David Carcache, Manuel Koller, Silvio Ofner, David Orain, Johanne Renaud
  • 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy
    Patent number: 8513268
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • Quinazoline derivatives
    Patent number: 8299085
    Abstract: The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: October 30, 2012
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Wolfgang Froestl, Manuel Koller, Henri Mattes, Joachim Nozulak, Silvio Ofner, David Orain, Vittorio Rasetti, Johanne Renaud, Nicolas Soldermann, Philipp Floersheim
  • FTY720 HALOGENATED DERIVATIVES
    Publication number: 20120244071
    Abstract: There are provided new iodo- and bromo-compounds, and their use as diagnostic agents and imaging agents for diseases and disorders wherein S1P receptor expression is altered.
    Type: Application
    Filed: December 8, 2010
    Publication date: September 27, 2012
    Applicant: Novartis AG
    Inventors: Yves Auberson, Emmanuelle Briard, David Orain
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20110294818
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide
    Patent number: 8012988
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: September 6, 2011
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • Organic compounds
    Patent number: 7786155
    Abstract: The invention relates to compound of the formula I wherein the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: August 31, 2010
    Assignee: Novartis AG
    Inventors: Joachim Nozulak, David Orain